Please use this identifier to cite or link to this item:
Title: Plasmodium falciparum pre-erythrocytic stage vaccine development
Authors: Molina Franky, Jessica
Cuy Chaparro, Laura
Camargo, Anny
Reyes, César
Gómez, Marcela
Salamanca, David Ricardo
Patarroyo, Manuel Alfonso
Patarroyo, Manuel Elkin
Issue Date: 2020
Citation: Molina-Franky, J., Cuy-Chaparro, L., Camargo, A., Reyes, C., Gómez, M., Salamanca, D. R., . . . Patarroyo, M. E. (2020). Plasmodium falciparum pre-erythrocytic stage vaccine development. Malaria Journal, 19(1) doi:10.1186/s12936-020-3141-z
Series/Report no.: Malaria Journal;Vol.19, No. 1,3 Feb 2020 Article number 56 páginas 1-18
Abstract: Worldwide strategies between 2010 and 2017 aimed at controlling malarial parasites (mainly Plasmodium falciparum) led to a reduction of just 18% regarding disease incidence rates. Many biologically-derived anti-malarial vaccine candidates have been developed to date; this has involved using many experimental animals, an immense amount of work and the investment of millions of dollars. This review provides an overview of the current state and the main results of clinical trials for sporozoite-targeting vaccines (i.e. the parasite stage infecting the liver) carried out by research groups in areas having variable malaria transmission rates. However, none has led to promising results regarding the effective control of the disease, thereby making it necessary to complement such efforts at finding/introducing new vaccine candidates by adopting a multi-epitope, multi-stage approach, based on minimal subunits of the main sporozoite proteins involved in the invasion of the liver.
Appears in Collections:CCB. Artículos indexados en Scopus

Files in This Item:
File Description SizeFormat 
Plasmodium falciparum pre‑erythrocytic.pdf2,86 MBAdobe PDFThumbnail

This item is licensed under a Creative Commons License Creative Commons